Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by market cap, the company's primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars

#earnings